DoH Policies screened during the period – 1 October 2025 – 31 December 2025
Date published:
In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact.
Documents
- 5 Moments for Medication Safety: Patient Safety Toolkit (PDF 424KB)
- A Guide to Developing the Role of Advanced Practice Pharmacists in Northern Ireland (PDF 356KB)
- Amendment of The Regulation and Improvement Authority (Fees and Frequency of Inspections) Regulations 2005 (PDF 265KB)
- Cancer Charity Grant Scheme (PDF 382KB)
- NICE Public Health Guideline NG247 - Maternal and child nutrition: nutrition and weight management in pregnancy, and nutrition in children up to 5 years (PDF 384KB)
- NICE Clinical Guideline NG250 - Pneumonia: diagnosis and management (PDF 385KB)
- NICE Clinical Guideline NG252 - Rehabilitation for chronic neurological disorders including acquired brain injury (PDF 384KB)
- Provision of Therapeutic Intervention services, including counselling to adults who have experienced sexual violence and abuse (PDF 555KB)
- NICE Technology Appraisal TA1098 - Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable (PDF 300KB)
- NICE Technology Appraisal TA1099 - Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy (PDF 300KB)
- NICE Technology Appraisal TA1101 - Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over (PDF 301KB)
- NICE Technology Appraisal TA1103 - Lorlatinib for ALK-positive advanced non[1]small-cell lung cancer that has not been treated with an ALK inhibitor (review of TA909) (PDF 320KB)
- NICE Technology Appraisal TA1106 - Cabotegravir for preventing HIV-1 in adults and young people (PDF 305KB)
- NICE Technology Appraisal TA1107 - Delgocitinib for treating moderate to severe chronic hand eczema (PDF 305KB)
- NICE Technology Appraisal TA1108 - Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer (PDF 300KB)
- NICE Technology Appraisal TA1109 - Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer (PDF 300KB)
- NICE Technology Appraisal TA1110 - Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (review of TA721) (PDF 325KB)
- NICE Technology Appraisal TA1113 - Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma (PDF 324KB)
- NICE Technology Appraisal TA1114 - Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (PDF 319KB)
- NICE Technology Appraisal TA1115 - Vutrisiran for treating transthyretin amyloidosis with cardiomyopathy (PDF 300KB)
- NICE Technology Appraisal TA1116 - Obecabtagene autoleucel for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (PDF 325KB)
- NICE Technology Appraisal TA1117 - Dostarlimab with platinum-containing chemotherapy for treating primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency (PDF 301KB)
- Valuing Medicines: A Strategy for the Sustainable Use of Medicines in Northern Ireland (PDF 465KB)